Sarepta Falls After Gene Therapy Elevidys Misses Estimates

Sarepta Therapeutics Inc. fell Monday after reporting its embattled gene therapy is expected to miss fourth-quarter sales estimates.

The company said preliminary sales of Elevidys, a therapy to treat a fatal muscle disorder, were $110 million in the last three months of 2025. That compares to the $122 million average estimate expected by Wall Street.